Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO William John Sibold Sells 5,221 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CEO William Sibold sold 5,221 shares of the company’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $542.39, for a total transaction of $2,831,818.19. Following the completion of the transaction, the chief executive officer owned 197,746 shares of the company’s stock, valued at $107,255,452.94. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

William John Sibold also recently made the following trade(s):

• On Wednesday, September 9th, William Sibold sold 6,362 shares of Madrigal Pharmaceuticals stock. The stock was sold at an average price of $535.59, for a total transaction of $3,407,423.58.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL stock opened at $534.49 on Friday. Madrigal Pharmaceuticals, Inc. has a 12 month low of $393.61 and a 12 month high of $615.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. The firm has a market capitalization of $12.35 billion, a P/E ratio of -41.47 and a beta of -0.98. The company’s fifty day moving average price is $530.99 and its two-hundred day moving average price is $507.63.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.69. The company had revenue of $364.25 million during the quarter, compared to analysts’ expectations of $352.13 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. The firm’s revenue for the quarter was up 71.2% on a year-over-year basis. During the same period in the prior year, the company posted ($1.90) EPS. On average, research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -7.03 earnings per share for the current fiscal year.

Institutional Trading of Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Tidal Investments LLC raised its stake in Madrigal Pharmaceuticals by 5.2% during the second quarter. Tidal Investments LLC now owns 1,631 shares of the biopharmaceutical company’s stock valued at $876,000 after buying an additional 80 shares in the last quarter. Engineers Gate Manager LP bought a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $709,000. Arizona State Retirement System grew its position in shares of Madrigal Pharmaceuticals by 1.5% in the 2nd quarter. Arizona State Retirement System now owns 4,114 shares of the biopharmaceutical company’s stock worth $2,209,000 after acquiring an additional 60 shares in the last quarter. Nykredit A S acquired a new position in shares of Madrigal Pharmaceuticals in the 2nd quarter worth approximately $356,000. Finally, Amundi grew its position in shares of Madrigal Pharmaceuticals by 13.2% in the 2nd quarter. Amundi now owns 1,386 shares of the biopharmaceutical company’s stock worth $744,000 after acquiring an additional 162 shares in the last quarter. 98.50% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. UBS Group restated a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Friday, July 31st. Canaccord Genuity Group increased their target price on Madrigal Pharmaceuticals from $578.00 to $587.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. HC Wainwright reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Friday, July 31st. Piper Sandler restated an “overweight” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target on the stock in a report on Tuesday, August 4th. Fifteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $699.64.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic diseases, particularly nonalcoholic steatohepatitis, now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH).

The company’s lead product is Rezdiffra (resmetirom), an oral, thyroid hormone receptor beta agonist designed to target underlying liver disease. In 2024, the U.S. Food and Drug Administration approved Rezdiffra for use with diet and exercise to treat adults with noncirrhotic MASH and moderate to advanced liver fibrosis.